Company Profile
Olema Pharmaceuticals, Inc. Stock Price, News & Catalysts
- Ticker:
- OLMA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.22 USD (-0.54%)
Close
Last updated: October 2, 2026
934M USD
Market cap
Why the stock is moving
The latest monitored company update is “Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Endocrine-Driven Cancer Company
Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer.
Palazestrant
Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast cancer.
OP-3136
OP-3136 is an oral KAT6 inhibitor intended to complement endocrine therapy and address transcriptional drivers of resistance.
Future catalysts
- Initiation of the Phase 1b/2 study of OP-3136 with darolutamide in metastatic castration-resistant prostate cancer in the fourth quarter of 2026.
- Topline results from the Phase 3 OPERA-01 palazestrant study in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Olema Pharmaceuticals, Inc. (OLMA)?
Olema Pharmaceuticals, Inc. (OLMA) most recently closed at 8.22 USD, a -0.54% move versus the previous session.
What is the market cap of Olema Pharmaceuticals, Inc. (OLMA)?
Olema Pharmaceuticals, Inc. currently has a market capitalization of 934M USD on BioPharmSignal.
What does Olema Pharmaceuticals, Inc. do?
Endocrine-Driven Cancer Company Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer. Palazestrant Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast cancer. OP-3136 OP-3136...
On which exchange is OLMA stock listed?
Olema Pharmaceuticals, Inc. (OLMA) is associated with NASDAQ, United States, Biopharma.
What is OP-3136?
Initiation of the Phase 1b/2 study of OP-3136 with darolutamide in metastatic castration-resistant prostate cancer in the fourth quarter of 2026.
Which conditions is Olema Pharmaceuticals, Inc. targeting with OP-3136?
Olema Pharmaceuticals, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Olema Pharmaceuticals, Inc. describe recent progress with OP-3136?
Initiation of the Phase 1b/2 study of OP-3136 with darolutamide in metastatic castration-resistant prostate cancer in the fourth quarter of 2026.
What is OPERA-01?
Topline results from the Phase 3 OPERA-01 palazestrant study in the first quarter of 2027.